PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CARBOPLATIN (CEC) FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM-CELL RESCUE IN WOMEN WITH METASTATIC OR HIGH-RISK NONMETASTATIC BREAST-CANCER - MULTIVARIATE-ANALYSIS OF FACTORS AFFECTING SURVIVAL AND ENGRAFTMENT
Tr. Klumpp et al., PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CARBOPLATIN (CEC) FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM-CELL RESCUE IN WOMEN WITH METASTATIC OR HIGH-RISK NONMETASTATIC BREAST-CANCER - MULTIVARIATE-ANALYSIS OF FACTORS AFFECTING SURVIVAL AND ENGRAFTMENT, Bone marrow transplantation, 20(4), 1997, pp. 273-281
Seventy women with high-risk stage II (n = 10), IIIA (n = 12), IIIB (n
= 11), or IV (n = 37) breast cancer received cyclophosphamide 6000 mg
/m(2), etoposide 2400 mg/m(2), and carboplatin 1200 mg/m(2) followed b
y infusion of autologous hematopoietic stem cells (AHSC). Women with h
igh-risk stage II disease had eight or more involved axillary lymph no
des (n = 9) or axillary and breast relapse following lumpectomy, chemo
therapy, and radiation therapy (n = 1). Women with measurable stage II
I or stage IV disease were required to demonstrate complete or partial
response to conventional-dose chemotherapy prior to transplant. The o
verall (complete plus partial) response rate for the 31 patients not i
n complete remission at the time of transplant was 55%. With a median
follow-up of 545 days, the 2-year actuarial progression-free survival
rates for patients with stage n, IIIA, IIIB and IV are 86, 75, 42 and
13%, respectively. Factors independently predictive of longer progress
ion-free survival by multivariate analysis included lower stage diseas
e, status of disease at transplant (in CR vs not in CR), and positive
estrogen receptor status. Factors predictive of more rapid neutrophil
engraftment by multivariate analysis included post-transplant administ
ration of hematopoietic growth factors, greater number of infused CFU-
GM, mobilization with G-CSF or cyclophosphamide/G-CSF (vs mobilization
with GM-CSF or no mobilization), and lower stage disease. Only one pa
tient (1.4%) died prior to day 100 from any cause. High-dose cyclophos
phamide, etoposide, and carboplatin followed by infusion of AHSC const
itutes an active and well-tolerated regimen in the treatment of women
with high-risk non-metastatic or metastatic breast cancer.